TRALI
- In 2019, a modified classification scheme was proposed based on new knowledge gained since the 2004 CCC (Canadian Consensus Conference). This classification, which was developed by a Delphi panel composed of international TRALI experts, reaffirmed that TRALI remains a clinical diagnosis and does not require detection of cognate leukocyte antibodies.
- What is TRALI 1 ?
No risk factors for ARDS and all the following criteria are met
- Acute onset
- Hypoxemia (PaO2/FiO2 ≤300 mmHg or SpO2 <90% on room air)
- Clear evidence of bilateral pulmonary edema on imaging
- No evidence of LAHΔ or, if LAH is present, it is judged to not be the main contributor to the hypoxemia
- Onset during or within 6 hours of transfusion◊
- No temporal relationship to an alternative risk factor for ARDS.
- What is TRALI 2?
Risk factors for ARDS are present (but ARDS has not been diagnosed) or mild ARDS at baseline* but with respiratory status deterioration that is judged to be due to transfusion based on both of the following:
Findings as described in categories a and b of TRALI type I
Stable respiratory status in the 12 hours before transfusion.
- What is TAD (Transfusion associated dyspnea)?
Used when pulmonary edema occurs greater than 6 hours after the transfusion and is clinically suspicious for temporal association with transfusion.
- How do we treat TRALI?
- Discontinuing of blood product.
- Supportive therapy with oxygen and if required ventilation with lung protective strategy
- Steroids are not recommended.
Comments
Post a Comment